MS
CRL icon

Maven Securities’s Charles River Laboratories CRL Stock Holding History

Maven Securities’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,200
Closed -$431K – 974
2023
Q3 		$431K Buy
+2,200
New +$452K ﹤0.01% 858

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Maven Securities's CRL Position: Q3 2021 in Review

Maven Securities sold out of Charles River Laboratories (CRL) in Q3 2021, closing a stake of 2,450 shares — an estimated $904K sold.

Maven Securities first reported a position in CRL in Q3 2020 and held it in 4 quarters. The position peaked at $2M in Q4 2020. 676 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

  • Maven Securities reported no remaining Charles River Laboratories position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 2,450 Charles River Laboratories shares in Q3 2021, an estimated $904K.
  • Maven Securities first reported a position in Charles River Laboratories in Q3 2020 and held it in 4 quarters.
  • Maven Securities's Charles River Laboratories position peaked at $2M in Q4 2020.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.